MedTrace Logo

Detecting Drugs of Abuse Via Exhaled Breath Samples Using Differential Mobility Spectrometry

NCT05384470 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2025-05-02

No results posted yet for this study

Summary

This Phase II STTR program consists of two major goals within the overarching goal of developing and validating a proprietary device (BID2) for marijuana and opioid detection in breath samples.

Conditions

  • Opiate Abuse
  • Marijuana Abuse
  • Diagnostic

Interventions

DRUG

Marihuana

Two doses of marijuana given.

DEVICE

BID2 Instrument - breathalyzer

The commercial device that we will be testing is designed to detect breath cannabinoid concentrations utilizing Differential Mobility Spectrometry technology, and was developed by Draper, to detect a wide range of chemicals and organisms in breath. Differential Mobility Spectrometry (DMS) is a robust, data-rich, ultra-trace, chemical detection technology. Unlike gas chromatography mass spectroscopy (GCMS) systems that are large and expensive, DMS is small, portable (approximately the size of a shoe box) and is able to measure the presence of volatile organic compounds (VOC) at parts per trillion (ppt) detection levels. The participant will exhale into the device via a plastic tube and the breath sample will be analyzed in situ. The participant does not come in contact with the device itself-they will simply exhale into a tube via a disposable mouthpiece.

Sponsors & Collaborators

  • VOX BIOMEDICAL LLC

    collaborator UNKNOWN

  • Mclean Hospital

    lead OTHER

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2024-03-19
Completion
2024-08-15
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05384470 on ClinicalTrials.gov